Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

周三，Oppenheimer重申了对Catalyst Pharmaceutical Partners (NASDAQ:CPRX)股票的"跑赢大盘"评级，目标价保持在29.00美元。这一积极展望是在Catalyst Pharmaceutical宣布与TEVA就Firdapse仿制药营销达成交割协议之后做出的。

根据Catalyst的说法，与其他ANDA申请者的诉讼可能会在2025年第四季度进入专利审判阶段。考虑到30个月的仿制药上市延迟期，这可能会将仿制药竞争推迟到至少2026年5月。管理层讨论表明，与首次申请者达成和解通常会导致与其他申请者迅速达成连续协议。

Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...